TORRENT PHARMACEUTICALS
|
|
BOM : 500420     NSE : TORNTPHARM     | |
LT :  
    Long Term Analysis
Fundamentals : Good
Valuation : Bad [Stock is Expensive] Debt : High |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Downward Pledged Shares : None or < 25% |
Sep 25,2023 |
Price(EOD): βΉ 1,847.25
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
MCap: βΉ 62,510.94 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
TORRENT PHARMACEUTICALS | -2% | -5.8% | 22.5% |
SUN PHARMACEUTICAL INDUSTRIES | -2.1% | 0.6% | 23.6% |
DIVIS LABORATORIES | -1.4% | 2% | 2% |
CIPLA | -5% | -3.3% | 8.7% |
DR REDDYS LABORATORIES | -5% | -7.9% | 30.8% |
ABBOTT INDIA | -2.8% | -2.2% | 24.5% |
ZYDUS LIFESCIENCES | -6.4% | -6% | 60.7% |
ALKEM LABORATORIES | -2.9% | -4.3% | 6.8% |
LUPIN | -2.5% | 2% | 63.4% |
FUNDAMENTAL ANALYSIS OF TORRENT PHARMACEUTICALS
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF TORRENT PHARMACEUTICALS
 Ratio | Consolidated | |
---|---|---|
P/E P/B P/S |
49.62
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 1,260.00 Cr
[Latest Qtr - Jun2023 - Consolidated Results ] 10.09
P/B Calculated based on Book Value of Rs 6,198.07 Cr
[Latest Year - Mar2023 - Consolidated Results ] 6.34
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 9,864.00 Cr
[Latest Qtr - Jun2023 - Consolidated Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
102% 207% 162% |
SHARE PRICE MOMENTUM OF TORRENT PHARMACEUTICALS
TORRENT PHARMACEUTICALS vs SENSEX
DEBT OF TORRENT PHARMACEUTICALS
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2022 2021 2020 Avg_3yrs |
0.53 0.73 1.04 0.77 |
0.68 0.83 1.21 0.91 |
[Last Annual Data : Mar2023]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF TORRENT PHARMACEUTICALS
Pledged Promoter Shares |
0 % | |
---|---|---|
As on : Jun2023 | ||
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF TORRENT PHARMACEUTICALS
Consolidated | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
4.01% 8.8% 22.63% 31.71% |
10.4% 11.1% -0.19% 6.78% |
QtrlyTrend |
6 | |
Latest Qtr: Jun2023 | ||
Quarterly Result Analysis → |
TORRENT PHARMACEUTICALS related INDICES
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
S&P BSE MID CAP | -1.3% | 3.7% | 25.8% |
S&P BSE MIDSMALLCAP | -1.6% | 3.3% | 26.5% |
S&P BSE LOW VOLATILITY | -1.7% | 1% | 18.5% |
S&P BSE ALLCAP | -2.2% | 1.9% | 13.3% |
S&P BSE 500 | -2.3% | 1.8% | 12.3% |
NSE Indices | 1W | 1M | 1Y |
---|---|---|---|
NIFTY ALPHA QTY LOW-VOLAT.30 | 0.2% | 2.3% | 19.1% |
NIFTY200 MOMENTUM 30 INDEX | -0.3% | 3.1% | 15.9% |
NIFTY ALPHA LOW-VOLATILTY 30 | -0.8% | 2% | 16.3% |
NIFTY 100 ALPHA 30 | -1.1% | 3.2% | -5.3% |
NIFTY LARGE MIDCAP 250 | -1.8% | 2.6% | 17.4% |
You may also like the below Video Courses
FAQ about TORRENT PHARMACEUTICALS
Is TORRENT PHARMACEUTICALS good for long term investment?
As on Sep 25,2023, the Fundamentals of TORRENT PHARMACEUTICALS look Strong and hence it may be good for long term investment! See Financial Performance of TORRENT PHARMACEUTICALS . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is TORRENT PHARMACEUTICALS UnderValued or OverValued?
As on Sep 25,2023, TORRENT PHARMACEUTICALS is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of TORRENT PHARMACEUTICALS ?
As on Sep 25,2023, the Intrinsic Value of TORRENT PHARMACEUTICALS is Rs. 704.51 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 913.22
Fair Value [Median EV / Sales Model] : Rs. 601.52
Fair Value [Median Price / Sales Model] : Rs. 704.51
Estimated Median Fair Value of TORRENT PHARMACEUTICALS : Rs. 704.51
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.
Is TORRENT PHARMACEUTICALS trading at a Premium or Discount?
As on Sep 25,2023, TORRENT PHARMACEUTICALS is trading at a Premium of 162% based on the estimates of Median Intrinsic Value!